Behavioral Health Partnerships Recent collaborations with Brookfield and HIAAH demonstrate demand for GeneSight pharmacogenomic testing to guide psychotropic prescriptions. This signals a clear sales path in behavioral health networks and community hospital systems. Target expansion to additional mental health providers with enterprise test offerings, provider training, and payer engagement to accelerate adoption.

Pharmacogenomics Growth Opportunities GeneSight has a long-running commercial PGx lab and sizable revenue, indicating market traction for pharmacogenomics. Expand cross-sell opportunities across oncology and other therapeutic areas within Myriad's portfolio, and pursue enterprise deals with payers and integrated health systems to scale adoption.

Marketing and Leadership Strategic investments in marketing and product leadership suggest a push to accelerate commercialization and customer success. Align BD efforts with the SVP of Marketing and VP of Product to develop evidence-based sales collateral, real-world outcomes, and co-marketing campaigns with payers and hospital networks to shorten sales cycles.

Data-Driven Care The GeneSight Mental Health Monitor study highlights data-driven insights into behavioral health. There is an opportunity to offer analytics dashboards and EMR/EHR integrations that demonstrate improved prescribing accuracy and patient outcomes to payers and providers, supporting ROI-driven selling.

Scale and Reimbursement With a mid-market revenue footprint and a growing provider network, there is potential to pursue broader market expansion through hospital systems and PBMs. Develop reimbursement-focused sales strategies and pricing models, and position pharmacogenomic testing as a value-based service that reduces adverse drug events and improves treatment efficacy.